SCHEMBL7216803

SCHEMBL7216803

CCOCCOc1cccc(NC(=O)c2c[nH]c3c2-c2nn(C)cc2CCC3)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.41
EPHX2 P34913 1/20 0.41
LMNA P02545 3/20 0.39
MET P08581 3/20 0.39
PRMT5 O14744 2/20 0.39
WDR77 Q9BQA1 2/20 0.39
THRB P10828 1/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7216469 0.90 NPC1 (0.42) NR3C1EPHX2SMN1; SMN2HPGDPOLB
SCHEMBL7217055 0.84 NPC1 (0.48) NR3C1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL6831069 0.79 NAMPT (0.53) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL7216265 0.78 NPC1 (0.38) NR3C1LMNAALDH1A1SMN1; SMN2HPGD
SCHEMBL7216626 0.77 APLNR (0.44) LMNASMN1; SMN2HPGDMEN1KMT2A
SCHEMBL7216812 0.76 NPC1 (0.56) LMNAALDH1A1SMN1; SMN2HPGDNPC1
SCHEMBL7367184 0.76 BRD4 (0.48) LMNATHRBSMN1; SMN2MEN1KMT2A
SCHEMBL6834487 0.76 GAA (0.43) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL7216549 0.75 ROCK2 (0.37) NR3C1LMNAPOLBNPC1TP53
SCHEMBL6834309 0.75 LMNA (0.42) LMNAALDH1A1SMN1; SMN2HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed